Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?
Autore:
Green, AI; Zimmet, SV; Strous, RD; Schildkraut, JJ;
Indirizzi:
Massachusetts Mental Hlth Ctr, Commonwealth Res Ctr, Boston, MA 02115 USA Massachusetts Mental Hlth Ctr Boston MA USA 02115 r, Boston, MA 02115 USA Harvard Med Sch, Dept Psychiat, Boston, MA USA Harvard Med Sch Boston MA USA ard Med Sch, Dept Psychiat, Boston, MA USA
Titolo Testata:
HARVARD REVIEW OF PSYCHIATRY
fascicolo: 6, volume: 6, anno: 1999,
pagine: 287 - 296
SICI:
1067-3229(199903/04)6:6<287:CFCSUD>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
VENTRAL TEGMENTAL AREA; SELF-MEDICATION HYPOTHESIS; FIRST-LINE TREATMENT; FREELY MOVING RATS; PREFRONTAL CORTEX; EXTRACELLULAR DOPAMINE; PSYCHIATRIC-SYMPTOMS; ANTIPSYCHOTIC-DRUGS; COGNITIVE FUNCTIONS; MENTAL-ILLNESS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
94
Recensione:
Indirizzi per estratti:
Indirizzo: Green, AI Massachusetts Mental Hlth Ctr, Commonwealth Res Ctr, 74 Fenwood Rd, Boston, Massachusetts Mental Hlth Ctr 74 Fenwood Rd Boston MA USA 02115
Citazione:
A.I. Green et al., "Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?", HARV R PSYC, 6(6), 1999, pp. 287-296

Abstract

Alcohol and other drugs of abuse are commonly used by persons with schizophrenia and contribute to the overall morbidity of the disorder. Standard, or typical, antipsychotic drugs do not limit such substance use and may evenrender it more likely. However, preliminary data from our group and otherssuggest that the atypical antipsychotic clozapine may decrease substance use in this population. While recognizing the likelihood that substance use decreases negative symptoms las well as extrapyramidal symptoms) in personswith schizophrenia, we hypothesize that the biological basis of substance use relates to a "reward-deficiency syndrome" secondary to dysfunctional dopamine-mediated mesocorticolimbic neurons in these individuals. We further suggest that clozapine's beneficial effect in patients with comorbid schizophrenia and substance use disorders may relate to its presumed ability to ameliorate the deficits in both the mesocortical and mesolimbic dopaminergicneuronal projections through its various actions on dopaminergic, serotonergic, and particularly noradrenergic neurons.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 14:49:03